These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 26075254)
21. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342 [TBL] [Abstract][Full Text] [Related]
22. Signaling pathways required for matrix metalloproteinase-9 induction by betacellulin in head-and-neck squamous carcinoma cells. O-charoenrat P; Wongkajornsilp A; Rhys-Evans PH; Eccles SA Int J Cancer; 2004 Aug; 111(2):174-83. PubMed ID: 15197768 [TBL] [Abstract][Full Text] [Related]
23. Synergistic Activity of Deguelin and Fludarabine in Cells from Chronic Lymphocytic Leukemia Patients and in the New Zealand Black Murine Model. Rebolleda N; Losada-Fernandez I; Perez-Chacon G; Castejon R; Rosado S; Morado M; Vallejo-Cremades MT; Martinez A; Vargas-Nuñez JA; Perez-Aciego P PLoS One; 2016; 11(4):e0154159. PubMed ID: 27101369 [TBL] [Abstract][Full Text] [Related]
24. Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells. Gan Y; Shi C; Inge L; Hibner M; Balducci J; Huang Y Oncogene; 2010 Sep; 29(35):4947-58. PubMed ID: 20562913 [TBL] [Abstract][Full Text] [Related]
26. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck. Amornphimoltham P; Patel V; Sodhi A; Nikitakis NG; Sauk JJ; Sausville EA; Molinolo AA; Gutkind JS Cancer Res; 2005 Nov; 65(21):9953-61. PubMed ID: 16267020 [TBL] [Abstract][Full Text] [Related]
27. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines. Li H; Schmid-Bindert G; Wang D; Zhao Y; Yang X; Su B; Zhou C Adv Med Sci; 2011; 56(2):275-84. PubMed ID: 22037177 [TBL] [Abstract][Full Text] [Related]
28. Evidence that basal activity, but not transactivation, of the epidermal growth factor receptor tyrosine kinase is required for insulin-like growth factor I-induced activation of extracellular signal-regulated kinase in oral carcinoma cells. Kuribayashi A; Kataoka K; Kurabayashi T; Miura M Endocrinology; 2004 Nov; 145(11):4976-84. PubMed ID: 15271882 [TBL] [Abstract][Full Text] [Related]
29. Deguelin, A PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/AKT pathway. Bortul R; Tazzari PL; Billi AM; Tabellini G; Mantovani I; Cappellini A; Grafone T; Martinelli G; Conte R; Martelli AM Br J Haematol; 2005 Jun; 129(5):677-86. PubMed ID: 15916691 [TBL] [Abstract][Full Text] [Related]
30. Role of nongenomic activation of phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase 1/2 pathways in 1,25D3-mediated apoptosis in squamous cell carcinoma cells. Ma Y; Yu WD; Kong RX; Trump DL; Johnson CS Cancer Res; 2006 Aug; 66(16):8131-8. PubMed ID: 16912191 [TBL] [Abstract][Full Text] [Related]
31. Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo. Bruzzese F; Di Gennaro E; Avallone A; Pepe S; Arra C; Caraglia M; Tagliaferri P; Budillon A Clin Cancer Res; 2006 Jan; 12(2):617-25. PubMed ID: 16428508 [TBL] [Abstract][Full Text] [Related]
32. Deguelin inhibits growth of breast cancer cells by modulating the expression of key members of the Wnt signaling pathway. Murillo G; Peng X; Torres KE; Mehta RG Cancer Prev Res (Phila); 2009 Nov; 2(11):942-50. PubMed ID: 19861542 [TBL] [Abstract][Full Text] [Related]
33. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells. Qin B; Ariyama H; Baba E; Tanaka R; Kusaba H; Harada M; Nakano S Cancer Chemother Pharmacol; 2006 Nov; 58(5):577-84. PubMed ID: 16532343 [TBL] [Abstract][Full Text] [Related]
34. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma. Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799 [TBL] [Abstract][Full Text] [Related]
35. Naphtho[1,2-b]furan-4,5-dione induces apoptosis of oral squamous cell carcinoma: involvement of EGF receptor/PI3K/Akt signaling pathway. Chien CM; Lin KL; Su JC; Chuang PW; Tseng CH; Chen YL; Chang LS; Lin SR Eur J Pharmacol; 2010 Jun; 636(1-3):52-8. PubMed ID: 20371243 [TBL] [Abstract][Full Text] [Related]
36. Magnolol induces apoptosis via inhibiting the EGFR/PI3K/Akt signaling pathway in human prostate cancer cells. Lee DH; Szczepanski MJ; Lee YJ J Cell Biochem; 2009 Apr; 106(6):1113-22. PubMed ID: 19229860 [TBL] [Abstract][Full Text] [Related]
37. CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells. Lin YC; Chen KC; Chen CC; Cheng AL; Chen KF Oral Oncol; 2012 Jul; 48(7):585-93. PubMed ID: 22342571 [TBL] [Abstract][Full Text] [Related]
38. Deguelin Induces the Apoptosis of Lung Squamous Cell Carcinoma Cells through Regulating the Expression of Galectin-1. Yan B; Zhao D; Yao Y; Bao Z; Lu G; Zhou J Int J Biol Sci; 2016; 12(7):850-60. PubMed ID: 27313498 [TBL] [Abstract][Full Text] [Related]
39. Deguelin suppresses cell proliferation via the inhibition of survivin expression and STAT3 phosphorylation in HTLV-1-transformed T cells. Ito S; Oyake T; Murai K; Ishida Y Leuk Res; 2010 Mar; 34(3):352-7. PubMed ID: 19781773 [TBL] [Abstract][Full Text] [Related]
40. Autocrine and paracrine chemokine receptor 7 activation in head and neck cancer: implications for therapy. Wang J; Seethala RR; Zhang Q; Gooding W; van Waes C; Hasegawa H; Ferris RL J Natl Cancer Inst; 2008 Apr; 100(7):502-12. PubMed ID: 18364504 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]